| Literature DB >> 35233354 |
Pao-Hui Tseng1,2,3, Li-Kung Wu4, Yi-Cheng Wang1, Tsung-Jung Ho4, Shinn-Zong Lin1, Sheng-Tzung Tsai1.
Abstract
Idiopathic normal pressure hydrocephalus (iNPH), albeit characterized by gait impairment, cognitive decline, and urinary incontinence, in clinical diagnosis is poorly defined and is usually coexistent with other neurodegenerative diseases. Surgical operation with shunt implantation is the primary treatment but leads to variable outcomes. Recent studies demonstrated that the pathophysiology of iNPH may include both preceding cerebrovascular events and concomitant Alzheimer's dementia or dopaminergic degenerative neuropathology in patients' brain. These factors not only help differentiate iNPH from its mimics but also associated with the extent of symptomatic improvement after surgery. In this review, we examined these mechanisms underlying the development of iNPH and the beneficial effects of shunt surgery. Furthermore, the increasing identification and importance of biomarkers from cerebrospinal fluid and neural imaging could also predict the responsiveness of treatment. Finally, these progresses suggest that combination therapy would be necessary for iNPH treatment in the future. Copyright:Entities:
Keywords: Acupuncture; Biomarker; Clinical outcome; Normal pressure hydrocephalus; Shunt
Year: 2021 PMID: 35233354 PMCID: PMC8830549 DOI: 10.4103/tcmj.tcmj_275_20
Source DB: PubMed Journal: Tzu Chi Med J ISSN: 1016-3190
Biomarkers from cerebrospinal fluid involving various pathophysiologies to predict idiopathic normal pressure hydrocephalus
| Biomarkers | Reliability | |||||
|---|---|---|---|---|---|---|
| Neuroinflammation [ | IL-6 | IFN-r | IL-10 | IL-1β | IL-4 | High correlation |
| Level (pg/mL) | 53.41-102.53 | 1.35-2.11 | 4.57-6.18 | 2.82-4.96 | 2.5-4.86 | |
| Alzheimer’s dementia [ | Ab42 | T-TAU | P-TAU | Exploring | ||
| Level (pg/mL) | 308.43-318 | 662.79-980 | 77.71–96 | |||
| Blood–brain barrier [ | sPDGFRβ | Exploring not define yet | ||||
| Level (ng/mL) | 750–850 | |||||
| Neurodegeneration [ | NfL | Debating | ||||
| Level (pg/mL) | 903–2419 | |||||
Cytokines: IL-6, IFN-r, IL-10, IL-1β, IL-4; Ab42: β-amyloid 42. t-tau: Total tau, p-tau: Phospho-tau, sPDGFRβ: Soluble platelet-derived growth factor receptor-beta, NfL: Neurofilament light chain, IL: Interleukin, IFN: Interferon
Clinical studies of shunt surgery for idiopathic normal pressure hydrocephalus patients, including patients’ characteristics, shunt design, and specific outcome analysis
| Author | Years | Design | Follow-up | Participant (subject numbers) | Treatment | Outcome measured | Results |
|---|---|---|---|---|---|---|---|
| Wu | 2019 | Retrospective study | Mean duration 1.73 years | 116 patients received a VPS, median age 76. 75 objective LD responders and 41 subjective LD responders | VPS | iNPHGS. MMSE, BBS | Positive LD trial predicted 82.8% of objective or subjective response patients |
| Grasso | 2019 | Retrospective study; clinical symptoms and outcome after ventriculoperitoneal shunt | Early follow-up (1-3 years postoperatively), short-term follow-up (3-5 years postoperatively), midterm follow-up (5-7 years postoperatively), long-term follow-up (7-10 years postoperatively) | 50 patients, median age 71 (37 men, 13 women) | VPS with programmable valve | iNPHGS. MMSE mRS, TUG, TMT, BI ADLs, ICIQ-SF | Gait showed better and sustained improvement. Cognitive impairment and urinary incontinence improved in the early follow-up |
| Modesto and Pinto [ | 2019 | Control clinical trial with home physical exercise program | Pretreatment home training, post-VP shunt treatment, and an additional 8-week treatment | 52 patients, mean age 74, 30 women and 22 men without VPS (F17/M9) with VPS (F13/M13) | With/without VPS | iNPHGS, MMSE, Dynamic Gait Index, FIM, TUG, BBS | Significant improvement with 10 weeks of home physical exercises in ADL and static balance and functional capacity for two groups. Additional improvement with VP shunt |
| Miyajima | 2016 | Prospective multileft study | At 3 months and 1 year after surgery | 83 patients, median age 76 | LPS | mRS, iNPHGS | 63% LPS patients improvement of at least 1 point in their mRS score, serious adverse events not significantly different between the groups at 1 year after surgery |
| Israelsson | 2020 | Population-based controls study | Mean duration 21 months (6-45 months after surgery) | 176 patients and 368 controls. Age 60-85 | Shunted | EQ5D5L | Shunting improved QoL and health status in all dimensions |
| Razay | 2019 | Prospective observational cross-section and cohort study | 12 months after VP shunt | 408 patients. Median age 77 | VPS | MMSE, Tinetti tests, Tandem walk test | 96% of participants following shunting, over 25% improved in either MMSE or balance/gait scores |
| Isik | 2019 | Retrospective study | Before and after CSF removal | 42 patients, median age 78 | Recurrent CSF removal only | MMSE, FAB, Stroop test, POMA, TUG, NHPT | The mean TUG scores decreased after the first, second, and third procedures |
| Peterson | 2016 | Whether apathetic symptoms improve following shunt surgery in NPH | Median 4.17 months follow-up | 22 patients, 49-83 age | VPS | MMSE, AES, GDS | Greater preoperative ventriculomegaly was associated with increased level of apathy and depression |
| Junkkari | 2017 | Prospective study | 3 and 12 months postoperative follow-up | 145 patients, median age 74 | VPS | 15D questionnaire | 63 (43%) patients had experienced a clinically significant improvement in HRQoL. Lower body mass index predicted favorable HRQoL outcome 1 year after the shunting |
LD: Lumbar drain, iNPH: Idiopathic normal-pressure hydrocephalus, CSF: Cerebrospinal fluid, VPSs: Ventriculoperitoneal shunts, LPSs: Lumboperitoneal shunts, HRQoL: Health-related quality of life, EQ5D5L: EuroQol 5-dimension 5-level, iNPHGS: iNPH grading scale, MMSE: Mini-mental state examination, BBS: Berg Balance Scale, mRS: Modified Rankin Scale, TUG: Timed up and go test, TMT: Tinetti mobility test, BI ADLs: Barthel index of activities of daily living, ICIQ-SF: International Consultation on Incontinence Modular Questionnaire Urinary Incontinence Short Form, FIM: Functional Independence Measure scale, Tinetti tests (POMA): Tinetti Performance Oriented Mobility Assessment, FAB: Frontal assessment battery, NHPT: Nine-hole peg test, AES: Apathy evaluation scale, GDS: Geriatric Depression Scale, CACI: Charlson age comorbidity index, BMI: Body mass index